Review
Anticoagulant-related bleeding: Clinical epidemiology, prediction, and prevention

https://doi.org/10.1016/0002-9343(93)90285-WGet rights and content

Abstract

objective: To review (1) the clinical epidemiology of bleeding during anticoagulant therapy with heparin or warfarin, (2) data useful in estimating the risk for bleeding in individual patients, and (3) the efficacy of methods for its prevention.

methods: Relevant literature was identified by a computerized search of the Medline database and by review of the bibliographies of original and review articles. Studies were classified according to their design. Estimates of the risk for bleeding during anticoagulant therapy, compared with the risk without therapy, were obtained from randomized trials. Estimates of the frequency of bleeding during the course of anticoagulant therapy and information about risk factors for bleeding were obtained primarily from longitudinal studies of inception cohorts of patients followed from the start of therapy.

main results: The average daily frequencies of fatal, major, and major or minor bleeding during heparin therapy were 0.05%, 0.8%, and 2.0%, respectively; these frequencies are approximately twice those expected without heparin therapy. The average annual frequencies of fatal, major, and major or minor bleeding during warfarin therapy were 0.6%, 3.0%, and 9.6%, respectively; these frequencies are approximately five times those expected without warfarin therapy. The risk for anticoagulant-related bleeding is highest at the start of therapy: during warfarin therapy, the risk for major bleeding during the first month of therapy is approximately 10 times the risk after the first year of therapy. An individual patient's risk for major anticoagulant-related bleeding can be estimated on the basis of specific risk factors such as the intensity of the anticoagulant effect achieved and the presence of serious comorbid diseases, especially cerebrovascular, kidney, heart, and liver disease; older age and concurrent medicines may also be independent risk factors. Major bleeding most often affects the gastrointestinal tract, soft tissues, and urinary tract. Diagnostic evaluation of gastrointestinal bleeding and gross hematuria leads to identification of previously unknown lesions in approximately one-third of cases, even when the prothrombin time is elevated. Intracranial bleeding is rare, but it is frequently fatal. The frequency of bleeding during warfarin therapy is reduced by less intense therapy achieving a prothrombin time with an International Normalized Ratio of 2.0 to 3.0, which is efficacious for most indications.

conclusion: Anticoagulant-related bleeding is common and often serious. The risk for bleeding can be estimated in an individual patient, giving the primary physician a quantitative basis for weighing the risks and benefits of therapy and for optimizing patient management. The frequency of anticoagulant-related bleeding is reduced by less intense warfarin therapy. Future studies should evaluate new approaches to management that may further reduce complications while maintaining efficacy.

References (124)

  • CJ Bjerkelund

    Therapeutic level in long-term anticoagulant therapy after myocardial infarction: its relation to recurrent infarction and sudden death

    Am J Cardiol

    (1963)
  • B Furie et al.

    Randomized prospective trial comparing the native prothrombin antigen with the prothrombin time for monitoring oral anticoagulant therapy

    Blood

    (1990)
  • D Petitti et al.

    Duration of warfarin anticoagulant therapy and the probabilities of recurrent thromboembolism and hemorrhage

    Am J Med

    (1986)
  • DB Petitti et al.

    Prothrombin time ratio and other factors associated with bleeding in patients treated with warfarin

    J Clin Epidemiol

    (1989)
  • JH Chesebro et al.

    Trial of combined warfarin plus dipyridamole or aspirin therapy in prosthetic heart valve replacement: danger of aspirin compared with dipyridamole

    Am J Cardiol

    (1983)
  • VJ Disesa et al.

    Hematological complications with the St. Jude valve and reduced-dose coumadin

    Ann Thorac Surg

    (1989)
  • CS Landefeld et al.

    Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy

    Am J Med

    (1989)
  • F El Baba et al.

    Massive hemorrhage complicating age-related macular degeneration: clinicopathologic correlation and role of anticoagulants

    Ophthalmology

    (1986)
  • LB McMahan

    Anticoagulants and cataract surgery

    J Cataract Refract Surg

    (1988)
  • CS Landefeld et al.

    A bleeding risk index for estimating the probability of major bleeding in hospitalized patients starting anticoagulant therapy

    Am J Med

    (1990)
  • JR Wilson et al.

    Heparin therapy: a randomized prospective study

    Am Heart J

    (1979)
  • JE Wilson et al.

    Heparin therapy in venous thromboembolism

    Am J Med

    (1981)
  • PG Bentley et al.

    An objective study of alternative methods of heparin administration

    Thromb Res

    (1980)
  • J Kashtan et al.

    Heparin therapy for deep venous thrombosis

    Am J Surg

    (1980)
  • B Furie et al.

    Comparison of the native prothrombin antigen and the prothrombin time for monitoring oral anticoagulant therapy

    Blood

    (1984)
  • RJ Kernohan et al.

    Heparin therapy in thromboembolic disease

    Lancet

    (1966)
  • Stroke prevention in atrial fibrillation study: final results

    Circulation

    (1991)
  • The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation

    N Engl J Med

    (1990)
  • P Smith et al.

    The effect of warfarin on mortality and reinfarction after myocardial infarction

    N Engl J Med

    (1990)
  • L Poller et al.

    Fixed minidose warfarin: a new approach to prophylaxis against venous thrombosis after major surgery

    BMJ

    (1987)
  • R Collins et al.

    Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin: overview of results of randomized trials in general, orthopedic, and urologic surgery

    N Engl J Med

    (1988)
  • T Lancaster et al.

    The impact of long-term warfarin therapy on quality of life: evidence from a randomized trial

    Arch Intern Med

    (1991)
  • HL Bussey et al.

    Reliance on prothrombin time ratios causes significant errors in anticoagulation therapy

    Arch Intern Med

    (1992)
  • P Theroux et al.

    Aspirin, heparin, or both to treat acute unstable angina

    N Engl J Med

    (1988)
  • AM Walker et al.

    Prediction of bleeding during heparin therapy

    JAMA

    (1980)
  • WW Coon et al.

    Hemorrhagic complications of anticoagulant therapy

    Arch Intern Med

    (1974)
  • EA Loeliger et al.

    A double-blind trial of long-term anticoagulant treatment after myocardial infarction

    Acta Med Scand

    (1967)
  • RN Baker

    An evaluation of anticoagulant therapy in the treatment of cerebrovascular disease: report of the Veterans Administration Cooperative Study of Atherosclerosis

    Neurology

    (1961)
  • E Enger et al.

    Long-term anticoagulant therapy in patients with cerebral infarction

    Acta Med Scand

    (1965)
  • F McDowell et al.

    Anticoagulant therapy: five years experience with the patient with an established cerebrovascular accident

    Arch Neurol

    (1963)
  • GG Turpiea et al.

    Randomised comparison of two intensities of oral anticoagulant therapy after tissue heart valve replacement

    Lancet

    (1988)
  • JN Saour et al.

    Trial of different intensities of anticoagulation in patients with prosthetic heart valves

    N Engl J Med

    (1990)
  • OJAT euwissen et al.

    Double blind trial of long-term anticoagulant treatment after myocardial infarction

    Acta Med Scand

    (1969)
  • RH White et al.

    Home prothrombin time monitoring after the initiation of warfarin therapy: a randomized, prospective study

    Ann Intern Med

    (1989)
  • U Bynum et al.

    Low-dose heparin therapy in the long-term management of venous thromboembolism

    Am J Med

    (1979)
  • R Hull et al.

    Warfarin sodium versus low-dose heparin in the long-term treatment of venous thrombosis

    N Engl J Med

    (1979)
  • R Hull et al.

    Adjusted subcutaneous heparin versus warfarin sodium in the long-term treatment of venous thrombosis

    N Engl J Med

    (1982)
  • R Hull et al.

    Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis

    N Engl J Med

    (1982)
  • RD Hull et al.

    Heparin for five days as compared with ten days in the initial treatment of proximal venous thrombosis

    N Engl J Med

    (1990)
  • MA Fitzpatrick et al.

    An audit of anticoagulation and endocarditis prophylaxis after heart valve surgery

    N Z Med J

    (1991)
  • Cited by (811)

    • Nanomaterials for Fluorescent Detection of Hemoglobin

      2024, Critical Reviews in Analytical Chemistry
    View all citing articles on Scopus
    1

    Dr. Landefeld is an American College of Physicians George Morris Piersol Teaching and Research Scholar. This work was supported in part by a grant from the National Institute on Aging (RO1 AG09657-01).

    View full text